CDER Officials Testify On Behind-The-Scenes Maneuvers In Plan B Rejection
This article was originally published in The Tan Sheet
Executive Summary
The initial rejection of Barr's Rx-to-OTC switch application for Plan B may have been intended to lead eventually to a restricted approval, according to deposition testimony from FDA officials
You may also be interested in...
Plan B Pioneers OTC “Pharmacy Counter” Approval, Dual-Status Marketing
FDA's decision to approve emergency contraceptive Plan B for over-the-counter sale to women age 18 and older cracks open the door on a pharmacy-only, behind-the-counter model for nonprescription drug sales
FDA Depositions Reveal Crawford’s Prominent Role In Plan B Switch Review
The role of high-level FDA officials in the review of Barr Labs' Rx-to-OTC switch application for Plan B was required by the "high-profile" nature of the NDA, according to Center for Drug Evaluation & Research Director Steven Galson
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement